-
2
-
-
78549263792
-
Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla(R)): A review of its use in the management of HIV infection
-
Deeks, E.D.; Perry, C.M. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla(R)): A review of its use in the management of HIV infection. Drugs 2010, 70, 2315-2338.
-
(2010)
Drugs
, vol.70
, pp. 2315-2338
-
-
Deeks, E.D.1
Perry, C.M.2
-
3
-
-
84862919908
-
-
U.S. Prescribing Information. Available online, (accessed on 1 December)
-
U.S. Prescribing Information. Available online: http://packageinserts. bms.com/pi/pi-sustiva.pdf (accessed on 1 December 2011).
-
(2011)
-
-
-
4
-
-
0032589627
-
Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: Species differences in the metabolism of efavirenz
-
Mutlib, A.E.; Chen, H.; Nemeth, G.A.; Markwalder, J.A.; Seitz, S.P.; Gan, L.S.; Christ, D.D. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: Species differences in the metabolism of efavirenz. Drug Metab. Dispos. 1999, 27, 1319-1333.
-
(1999)
Drug Metab. Dispos.
, vol.27
, pp. 1319-1333
-
-
Mutlib, A.E.1
Chen, H.2
Nemeth, G.A.3
Markwalder, J.A.4
Seitz, S.P.5
Gan, L.S.6
Christ, D.D.7
-
5
-
-
0038002981
-
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity
-
DOI 10.1124/jpet.103.049601
-
Ward, B.A.; Gorski, J.C.; Jones, D.R.; Hall, S.D.; Flockhart, D.A.; Desta, Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 2003, 306, 287-300. (Pubitemid 36734384)
-
(2003)
Journal of Pharmacology and Experimental Therapeutics
, vol.306
, Issue.1
, pp. 287-300
-
-
Ward, B.A.1
Gorski, J.C.2
Jones, D.R.3
Hall, S.D.4
Flockhart, D.A.5
Desta, Z.6
-
6
-
-
77953756056
-
Efavirenz primary and secondary metabolism in vitro and in vivo: Identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation
-
Ogburn, E.T.; Jones, D.R.; Masters, A.R.; Xu, C.; Guo, Y.; Desta, Z. Efavirenz primary and secondary metabolism in vitro and in vivo: Identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab. Dispos. 2010, 38, 1218-1229.
-
(2010)
Drug Metab. Dispos.
, vol.38
, pp. 1218-1229
-
-
Ogburn, E.T.1
Jones, D.R.2
Masters, A.R.3
Xu, C.4
Guo, Y.5
Desta, Z.6
-
7
-
-
79952607777
-
In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype
-
Rekic, D.; Roshammar, D.; Mukonzo, J.; Ashton, M. In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. Br. J. Clin. Pharmacol. 2011, 71, 536-543.
-
(2011)
Br. J. Clin. Pharmacol.
, vol.71
, pp. 536-543
-
-
Rekic, D.1
Roshammar, D.2
Mukonzo, J.3
Ashton, M.4
-
8
-
-
79956364942
-
Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites
-
Bae, S.K.; Jeong, Y.J.; Lee, C.; Liu, K.H. Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites. Xenobiotica 2011, 41, 437-444.
-
(2011)
Xenobiotica
, vol.41
, pp. 437-444
-
-
Bae, S.K.1
Jeong, Y.J.2
Lee, C.3
Liu, K.H.4
-
9
-
-
79953171166
-
Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz
-
Cho, D.Y.; Ogburn, E.T.; Jones, D.; Desta, Z. Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz. Antimicrob. Agents Chemother. 2011, 55, 1504-1509.
-
(2011)
Antimicrob. Agents Chemother.
, vol.55
, pp. 1504-1509
-
-
Cho, D.Y.1
Ogburn, E.T.2
Jones, D.3
Desta, Z.4
-
10
-
-
70349108450
-
Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine
-
Belanger, A.S.; Caron, P.; Harvey, M.; Zimmerman, P.A.; Mehlotra, R.K.; Guillemette, C. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab. Dispos. 2009, 37, 1793-1796.
-
(2009)
Drug Metab. Dispos.
, vol.37
, pp. 1793-1796
-
-
Belanger, A.S.1
Caron, P.2
Harvey, M.3
Zimmerman, P.A.4
Mehlotra, R.K.5
Guillemette, C.6
-
11
-
-
74549134800
-
UGT genomic diversity: Beyond gene duplication
-
Guillemette, C.; Levesque, E.; Harvey, M.; Bellemare, J.; Menard, V. UGT genomic diversity: Beyond gene duplication. Drug Metab. Rev. 2010, 42, 22-42.
-
(2010)
Drug Metab. Rev.
, vol.42
, pp. 22-42
-
-
Guillemette, C.1
Levesque, E.2
Harvey, M.3
Bellemare, J.4
Menard, V.5
-
12
-
-
67650821911
-
Quantitative analysis of UDP-glucuronosyl transferase (UGT) 1A and UGT2B expression levels in human livers
-
Izukawa, T.; Nakajima, M.; Fujiwara, R.; Yamanaka, H.; Fukami, T.; Takamiya, M.; Aoki, Y.; Ikushiro, S.; Sakaki, T.; Yokoi, T. Quantitative analysis of UDP-glucuronosyl transferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab. Dispos. 2009, 37, 1759-1768.
-
(2009)
Drug Metab. Dispos.
, vol.37
, pp. 1759-1768
-
-
Izukawa, T.1
Nakajima, M.2
Fujiwara, R.3
Yamanaka, H.4
Fukami, T.5
Takamiya, M.6
Aoki, Y.7
Ikushiro, S.8
Sakaki, T.9
Yokoi, T.10
-
13
-
-
58149467072
-
Determination of mRNA expression of human UDP-glucuronosyl transferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction
-
Ohno, S.; Nakajin, S. Determination of mRNA expression of human UDP-glucuronosyl transferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab. Dispos. 2009, 7, 32-40.
-
(2009)
Drug Metab. Dispos.
, vol.7
, pp. 32-40
-
-
Ohno, S.1
Nakajin, S.2
-
14
-
-
15244342411
-
UDP-glucuronosyltransferases and clinical drug-drug interactions
-
DOI 10.1016/j.pharmthera.2004.10.013
-
Kiang, T.K.; Ensom, M.H.; Chang, T.K. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol. Ther. 2005, 106, 97-132. (Pubitemid 40386722)
-
(2005)
Pharmacology and Therapeutics
, vol.106
, Issue.1
, pp. 97-132
-
-
Kiang, T.K.L.1
Ensom, M.H.H.2
Chang, T.K.H.3
-
15
-
-
79952479196
-
Effects of herbal supplements on drug glucuronidation. Review of clinical, animal, and in vitro studies
-
Mohamed, M.F.; Frye, R.F. Effects of herbal supplements on drug glucuronidation. Review of clinical, animal, and in vitro studies. Planta Med. 2011, 77, 311-321.
-
(2011)
Planta Med.
, vol.77
, pp. 311-321
-
-
Mohamed, M.F.1
Frye, R.F.2
-
16
-
-
0033926065
-
Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects
-
Ebert, U.; Thong, N.Q.; Qertel, R.; Kirch, W. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. Eur. J. Clin. Pharmacol. 2000, 56, 299-304. (Pubitemid 30462927)
-
(2000)
European Journal of Clinical Pharmacology
, vol.56
, Issue.4
, pp. 299-304
-
-
Ebert, U.1
Thong, N.Q.2
Oertel, R.3
Kirch, W.4
-
17
-
-
33746752084
-
Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects
-
DOI 10.1016/j.clpt.2006.04.014, PII S000992360600172X
-
van der Lee, M.J.; Dawood, I.; ter Hofstede, H.J.; de Graaff-Teulen, M.J.; van Ewijk-Beneken Kolmer, E.W.; Caliskan-Yassen, N.; Koopmans, P.P.; Burger, D.M. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin. Pharmacol. Ther. 2006, 80, 159-168. (Pubitemid 44160694)
-
(2006)
Clinical Pharmacology and Therapeutics
, vol.80
, Issue.2
, pp. 159-168
-
-
Van Der Lee, M.J.1
Dawood, L.2
Ter Hofstede, H.J.M.3
De Graaff-Teulen, M.J.A.4
Van Ewijk-Beneken Kolmer, E.W.J.5
Caliskan-Yassen, N.6
Koopmans, P.P.7
Burger, D.M.8
-
18
-
-
33344473930
-
Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline androsterone canrenoic acid hecogenin phenylbutazone quinidine quinine and sulfinpyrazone) "probes" for human UDP-glucuronosyltransferases
-
Uchaipichat, V.; Mackenzie, P.I.; Elliot, D.J.; Miners, J.O. Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human UDP-glucuronosyltransferases. Drug Metab. Dispos. 2006, 34, 449-456.
-
(2006)
Drug Metab. Dispos.
, vol.34
, pp. 449-456
-
-
Uchaipichat, V.1
Mackenzie, P.I.2
Elliot, D.J.3
Miners, J.O.4
-
19
-
-
30144436526
-
Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases
-
DOI 10.1016/S0076-6879(05)00007-8, PII S0076687905000078, 7, Phase II Conjugation Enzymes and Transport Systems
-
Court, M.H. Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol. 2005, 400, 104-116. (Pubitemid 43052418)
-
(2005)
Methods in Enzymology
, vol.400
, pp. 104-116
-
-
Court, M.H.1
-
20
-
-
77951296034
-
Validated assay for studying activity profiles of human liver UGTs after drug exposure: Inhibition and induction studies
-
Donato, M.T.; Montero, S.; Castell, J.V.; Gómez-Lechón, M.J.; Lahoz, A. Validated assay for studying activity profiles of human liver UGTs after drug exposure: Inhibition and induction studies. Anal. Bioanal. Chem. 2010, 96, 2251-2263.
-
(2010)
Anal. Bioanal. Chem.
, vol.96
, pp. 2251-2263
-
-
Donato, M.T.1
Montero, S.2
Castell, J.V.3
Gómez-Lechón, M.J.4
Lahoz, A.5
-
21
-
-
80052230944
-
Corydaline inhibits multiple cytochrome P450 and UDP- glucuronosyltransferase enzyme activities in human liver microsomes
-
Ji, H.Y.; Liu, K.H.; Lee, H.; Im, S.R.; Shim, H.J.; Son, M.; Lee, H.S. Corydaline inhibits multiple cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in human liver microsomes. Molecules 2011, 16, 6591-6602.
-
(2011)
Molecules
, vol.16
, pp. 6591-6602
-
-
Ji, H.Y.1
Liu, K.H.2
Lee, H.3
Im, S.R.4
Shim, H.J.5
Son, M.6
Lee, H.S.7
-
22
-
-
0035875828
-
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
-
DOI 10.1097/00002030-200101050-00011
-
Marzolini, C.; Telenti, A.; Decosterd, L.A.; Greub, G.; Biollaz, J.; Buclin, T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001, 15, 71-75. (Pubitemid 32055781)
-
(2001)
AIDS
, vol.15
, Issue.1
, pp. 71-75
-
-
Marzolini, C.1
Telenti, A.2
Decosterd, L.A.3
Greub, G.4
Biollaz, J.5
Buclin, T.6
-
23
-
-
77952314576
-
Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes
-
Bourcier, K.; Hyland, R.; Kempshall, S.; Jones, R.; Maximilien, J.; Irvine, N.; Jones, B. Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes. Drug Metab. Dispos. 2010, 38, 923-929.
-
(2010)
Drug Metab. Dispos.
, vol.38
, pp. 923-929
-
-
Bourcier, K.1
Hyland, R.2
Kempshall, S.3
Jones, R.4
Maximilien, J.5
Irvine, N.6
Jones, B.7
-
24
-
-
63849225944
-
In vitro and in vivo glucuronidation of midazolam in humans
-
Hyland, R.; Osborne, T.; Payne, A.; Kempshall, S.; Logan, Y.R.; Ezzeddine, K.; Jones, B. In vitro and in vivo glucuronidation of midazolam in humans. Br. J. Clin. Pharmacol. 2009, 67, 445-454.
-
(2009)
Br. J. Clin. Pharmacol.
, vol.67
, pp. 445-454
-
-
Hyland, R.1
Osborne, T.2
Payne, A.3
Kempshall, S.4
Logan, Y.R.5
Ezzeddine, K.6
Jones, B.7
-
25
-
-
2342572781
-
Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4
-
DOI 10.1016/j.bcp.2004.02.014, PII S0006295204001285
-
Kaku, T.; Ogura, K.; Nishiyama, T.; Ohnuma, T.; Muro, K.; Hiratsuka, A. Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem. Pharmacol. 2004, 67, 2093-2102. (Pubitemid 38595490)
-
(2004)
Biochemical Pharmacology
, vol.67
, Issue.11
, pp. 2093-2102
-
-
Kaku, T.1
Ogura, K.2
Nishiyama, T.3
Ohnuma, T.4
Muro, K.5
Hiratsuka, A.6
-
26
-
-
33646784394
-
In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction
-
DOI 10.1124/dmd.106.009340
-
Rowland, A.; Elliot, D.J.; Williams, J.A.; Mackenzie, P.I.; Dickinson, R.G.; Miners, J.O. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab. Dispos. 2006, 34, 1055-1062. (Pubitemid 43763765)
-
(2006)
Drug Metabolism and Disposition
, vol.34
, Issue.6
, pp. 1055-1062
-
-
Rowland, A.1
Elliot, D.J.2
Williams, J.A.3
Mackenzie, P.I.4
Dickinson, R.G.5
Miners, J.O.6
-
27
-
-
79959453365
-
In vitro investigation of human UDP-glucuronosyltransferase isoforms responsible for tacrolimus glucuronidation: Predominant contribution of UGT1A4
-
Laverdiere, I.; Caron, P.; Harvey, M.; Levesque, E.; Guillemette, C. In vitro investigation of human UDP-glucuronosyltransferase isoforms responsible for tacrolimus glucuronidation: Predominant contribution of UGT1A4. Drug Metab. Dispos. 2011, 39, 1127-1130.
-
(2011)
Drug Metab. Dispos.
, vol.39
, pp. 1127-1130
-
-
Laverdiere, I.1
Caron, P.2
Harvey, M.3
Levesque, E.4
Guillemette, C.5
-
28
-
-
79952819517
-
Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: Application to the reaction phenotyping of acetaminophen glucuronidation
-
Miners, J.O.; Bowalgaha, K.; Elliot, D.J.; Baranczewski, P.; Knights, K.M. Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: Application to the reaction phenotyping of acetaminophen glucuronidation. Drug Metab. Dispos. 2011, 39, 644-652.
-
(2011)
Drug Metab. Dispos.
, vol.39
, pp. 644-652
-
-
Miners, J.O.1
Bowalgaha, K.2
Elliot, D.J.3
Baranczewski, P.4
Knights, K.M.5
-
29
-
-
31744443743
-
In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP- glucuronosyltransferase 1A9 - Potent inhibition by niflumic acid
-
DOI 10.1002/bdd.475
-
Mano, Y.; Usui, T.; Kamimura, H. In vitro inhibitory effects of non-steroidal anti-inflammatory drugs on 4-methylumbelliferone glucuronidation in recombinant human UDP-glucuronosyltransferase 1A9-potent inhibition by niflumic acid. Biopharm. Drug Dispos. 2006, 27, 1-6. (Pubitemid 43173968)
-
(2006)
Biopharmaceutics and Drug Disposition
, vol.27
, Issue.1
, pp. 1-6
-
-
Mano, Y.1
Usui, T.2
Kamimura, H.3
-
31
-
-
3142512630
-
Stereoselectlve glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man
-
DOI 10.1080/00498250410001691280
-
Tougou, K.; Gotou, H.; Ohno, Y.; Nakamura, A. Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man. Xenobiotica 2004, 34, 449-461. (Pubitemid 38901455)
-
(2004)
Xenobiotica
, vol.34
, Issue.5
, pp. 449-461
-
-
Tougou, K.1
Gotou, H.2
Ohno, Y.3
Nakamura, A.4
-
32
-
-
0033786733
-
The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases
-
Lautala, P.; Ethell, B.T.; Taskinen, J.; Burchell, B. The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. Drug Metab. Dispos. 2000, 28, 1385-1389.
-
(2000)
Drug Metab. Dispos.
, vol.28
, pp. 1385-1389
-
-
Lautala, P.1
Ethell, B.T.2
Taskinen, J.3
Burchell, B.4
-
33
-
-
58549093350
-
Metabolism and renal elimination of gaboxadol in humans: Role of UDP-glucuronosyltransferases and transporters
-
Chu, X.Y.; Liang, Y.; Cai, X.; Cuevas-Licea, K.; Rippley, R.K.; Kassahun, K.; Shou, M.; Braun, M.P.; Doss, G.A.; Anari, M.R. Metabolism and renal elimination of gaboxadol in humans: Role of UDP-glucuronosyltransferases and transporters. Pharm. Res. 2009, 26, 459-468.
-
(2009)
Pharm. Res.
, vol.26
, pp. 459-468
-
-
Chu, X.Y.1
Liang, Y.2
Cai, X.3
Cuevas-Licea, K.4
Rippley, R.K.5
Kassahun, K.6
Shou, M.7
Braun, M.P.8
Doss, G.A.9
Anari, M.R.10
-
34
-
-
33646497843
-
N-Glucuronidation of the antiepileptic drug retigabine: Results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II
-
Borlak, J.; Gasparic, A.; Locher, M.; Schupke, H.; Hermann, R. N-Glucuronidation of the antiepileptic drug retigabine: Results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II. Metabolism 2006, 55, 711-721.
-
(2006)
Metabolism
, vol.55
, pp. 711-721
-
-
Borlak, J.1
Gasparic, A.2
Locher, M.3
Schupke, H.4
Hermann, R.5
-
35
-
-
18144406492
-
Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases
-
DOI 10.1124/dmd.105.004093
-
Luukkanen, L.; Taskinen, J.; Kurkela, M.; Kostiainen, R.; Hirvonen, J.; Finel, M. Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases. Drug Metab. Dispos. 2005, 33, 1017-1026. (Pubitemid 41002784)
-
(2005)
Drug Metabolism and Disposition
, vol.33
, Issue.7
, pp. 1017-1026
-
-
Luukkanen, L.1
Taskinen, J.2
Kurkela, M.3
Kostiainen, R.4
Hirvonen, J.5
Finel, M.6
|